The European Commission announced on Tuesday 21 September that it had signed a new group purchase contract for a candidate treatment against Covid-19.
The treatment in question - which is still undergoing a rolling review by the European Medicines Agency (EMA) - combines the antibodies bamlanivimab and etesevimab, and is being developed by the American pharmaceutical company Eli Lilly.
It was identified last June by the Commission as one of the five “most promising” treatment solutions...